Benitec Biopharma Inc BNTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Trading Information
- Previous Close Price
- $8.64
- Day Range
- $8.78–8.78
- 52-Week Range
- $7.51–15.80
- Bid/Ask
- $8.55 / $8.86
- Shares Outstanding
- 34.89M
- Market Cap
- $300.05M
- Volume/Avg
- 492 / 185,436
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 24
- Website
- https://www.benitec.com
Valuation
Metric | BNTC |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.68 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BNTC
Financial Strength
Metric | BNTC |
|---|---|
Quick Ratio | 33.68 |
Current Ratio | 34.00 |
Interest Coverage | — |
Quick Ratio
BNTC
Profitability
Metric | BNTC |
|---|---|
Return on Assets (Normalized) | −12.66% |
Return on Equity (Normalized) | −12.95% |
Return on Invested Capital (Normalized) | −16.63% |
Return on Assets
BNTC
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|jrCV#R | LOCK|h>x>k | $138B | |||
| Moderna Inc MRNA | LOCK|W#D^$%< | LOCK|xR | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|bDT^GRg | LOCK|!SMQ | $93B | |||
| argenx SE ADR ARGX | LOCK|^@!Q$H | LOCK|&! | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|TWJtd? | LOCK|sxn | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|@%l??$T | LOCK|v%JC | $30B | |||
| Incyte Corp INCY | LOCK|c@Yt<d# | LOCK|?q$ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|j<<?qX# | LOCK|qW# | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%>wYnwf | LOCK|^kDt | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|D%Y@#l | LOCK|%? | $15B |
United States